

---

---

# A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

**BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:**

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is  
2 amended as follows:

3 1. By amending subsection (d) to read:

4 "(d) Any material, compound, mixture, or preparation that  
5 contains any quantity of the following hallucinogenic  
6 substances, their salts, isomers, and salts of isomers, unless  
7 specifically excepted, whenever the existence of these salts,  
8 isomers, and salts of isomers is possible within the specific  
9 chemical designation:

- 10 (1) Alpha-ethyltryptamine (AET);  
11 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);  
12 (3) 2,5-dimethoxyamphetamine (2,5-DMA);  
13 (4) 3,4-methylenedioxy amphetamine;  
14 (5) 3,4-methylenedioxymethamphetamine (MDMA);  
15 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-  
16 MDA);  
17 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);  
18 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;



- 1 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- 2 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- 3 (11) 3,4,5-trimethoxy amphetamine;
- 4 (12) Bufotenine;
- 5 (13) 4-methoxyamphetamine (PMA);
- 6 (14) Diethyltryptamine;
- 7 (15) Dimethyltryptamine;
- 8 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 9 (17) Gamma hydroxybutyrate (GHB) (some other names include
- 10 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
- 11 hydroxybutanoic acid; sodium oxybate; sodium
- 12 oxybutyrate);
- 13 (18) Ibogaine;
- 14 (19) Lysergic acid diethylamide;
- 15 (20) Marijuana;
- 16 (21) Parahexyl;
- 17 (22) Mescaline;
- 18 (23) Peyote;
- 19 (24) N-ethyl-3-piperidyl benzilate;
- 20 (25) N-methyl-3-piperidyl benzilate;
- 21 (26) Psilocybin;
- 22 (27) Psilocyn;



- 1 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
- 2 (29) Ethylamine analog of phencyclidine (PCE);
- 3 (30) Pyrrolidine analog of phencyclidine (PCPy, PHP);
- 4 (31) Thiophene analog of phencyclidine (TCP; TCP);
- 5 (32) Gamma-butyrolactone, including butyrolactone;
- 6 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 7 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
- 8 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
- 9 hydroxybutyric acid lactone; 3-hydroxybutyric acid
- 10 lactone and 4-hydroxybutanoic acid lactone with
- 11 Chemical Abstract Service number 96-48-0 when any such
- 12 substance is intended for human ingestion;
- 13 (33) 1,4 butanediol, including butanediol; butane-1,4-diol;
- 14 1,4- butylenes glycol; butylene glycol; 1,4-
- 15 dihydroxybutane; 1,4- tetramethylene glycol;
- 16 tetramethylene glycol; tetramethylene 1,4- diol with
- 17 Chemical Abstract Service number 110-63-4 when any
- 18 such substance is intended for human ingestion;
- 19 (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
- 20 its optical isomers, salts, and salts of isomers;
- 21 (35) N-benzylpiperazine (BZP; 1-benzylpiperazine) its
- 22 optical isomers, salts, and salts of isomers;



- 1 (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its  
2 optical isomers, salts, and salts of isomers;
- 3 (37) Alpha-methyltryptamine (AMT), its isomers, salts, and  
4 salts of isomers;
- 5 (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its  
6 isomers, salts, and salts of isomers;
- 7 (39) Salvia divinorum;
- 8 (40) Salvinorin A;
- 9 (41) Divinorin A; [~~and~~]
- 10 (42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some  
11 trade or other names: 5-methoxy-3-[2-  
12 (dimethylamino)ethyl]indole; 5-MeO-DMT) [-];
- 13 (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 14 (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
- 15 (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
- 16 (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
- 17 (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-  
18 2);
- 19 (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine  
20 (2C-T-4);
- 21 (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 22 (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);



- 1        (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);  
2        (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
3        methoxybenzyl)ethanamine, its optical, positional, and  
4        geometric isomers, salts, and salts of isomers (Other  
5        names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);  
6        (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
7        methoxybenzyl)ethanamine, its optical, positional, and  
8        geometric isomers, salts, and salts of isomers (Other  
9        names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and  
10       (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
11       methoxybenzyl)ethanamine, its optical, positional, and  
12       geometric isomers, salts, and salts of isomers (Other  
13       names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."

14       2. By amending subsection (g) to read:

15       "(g) Any of the following cannabinoids, their salts,  
16 isomers, and salts of isomers, unless specifically excepted,  
17 whenever the existence of these salts, isomers, and salts of  
18 isomers is possible within the specific chemical designation:

- 19       (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols  
20 naturally contained in a plant of the genus Cannabis  
21 (cannabis plant), as well as synthetic equivalents of  
22 the substances contained in the plant, or in the



1           resinous extractives of Cannabis, sp. or synthetic  
2           substances, derivatives, and their isomers with  
3           similar chemical structure and pharmacological  
4           activity to those substances contained in the plant,  
5           such as the following: Delta 1 cis or trans  
6           tetrahydrocannabinol, and their optical isomers; Delta  
7           6 cis or trans tetrahydrocannabinol, and their optical  
8           isomers; and Delta 3,4 cis or trans-  
9           tetrahydrocannabinol, and its optical isomers (since  
10          nomenclature of these substances is not  
11          internationally standardized, compounds of these  
12          structures, regardless of numerical designation of  
13          atomic positions, are covered);  
14          (2) Naphthoylindoles; meaning any compound containing a  
15          3-(1-naphthoyl) indole structure with substitution at  
16          the nitrogen atom of the indole ring by a alkyl,  
17          haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
18          1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
19          ethyl group, whether or not further substituted in the  
20          indole ring to any extent and whether or not  
21          substituted in the naphthyl ring to any extent;

- 1 (3) Naphthylmethyloindoles; meaning any compound containing  
2 a 1H-indol-3-yl-(1-naphthyl) methane structure with  
3 substitution at the nitrogen atom of the indole ring  
4 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
5 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  
6 2-(4-morpholinyl) ethyl group whether or not further  
7 substituted in the indole ring to any extent and  
8 whether or not substituted in the naphthyl ring to any  
9 extent;
- 10 (4) Naphthoylpyrroles; meaning any compound containing a  
11 3-(1-naphthoyl) pyrrole structure with substitution at  
12 the nitrogen atom of the pyrrole ring by a alkyl,  
13 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
14 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
15 ethyl group whether or not further substituted in the  
16 pyrrole ring to any extent, whether or not substituted  
17 in the naphthyl ring to any extent;
- 18 (5) Naphthylmethyloindenes; meaning any compound containing  
19 a naphthylideneindene structure with substitution at  
20 the 3-position of the indene ring by a alkyl,  
21 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
22 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)



- 1 ethyl group whether or not further substituted in the  
2 indene ring to any extent, whether or not substituted  
3 in the naphthyl ring to any extent;
- 4 (6) Phenylacetylindoles; meaning any compound containing a  
5 3-phenylacetylindole structure with substitution at  
6 the nitrogen atom of the indole ring by a alkyl,  
7 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
8 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
9 ethyl group whether or not further substituted in the  
10 indole ring to any extent, whether or not substituted  
11 in the phenyl ring to any extent;
- 12 (7) Cyclohexylphenols; meaning any compound containing a  
13 2-(3-hydroxycyclohexyl) phenol structure with  
14 substitution at the 5-position of the phenolic ring by  
15 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
16 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or  
17 2-(4-morpholinyl) ethyl group whether or not  
18 substituted in the cyclohexyl ring to any extent;
- 19 (8) Benzoylindoles; meaning any compound containing a  
20 3-(benzoyl) indole structure with substitution at the  
21 nitrogen atom of the indole ring by a alkyl,  
22 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,





- 1 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)  
2 ethyl group whether or not further substituted in the  
3 indole ring to any extent and whether or not  
4 substituted in the phenyl ring to any extent;
- 5 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)  
6 pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-  
7 naphthalenylmethanone (another trade name is WIN  
8 55,212-2);
- 9 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-  
10 methyloctan-2-yl)-6a,7,10,10a-  
11 tetrahydrobenzo[c]chromen-1-ol (other trade names are:  
12 HU-210 and HU-211); [~~and~~]
- 13 (11) Tetramethylcyclopropanoylindoles; meaning any compound  
14 containing a 3-tetramethylcyclopropanoylindole  
15 structure with substitution at the nitrogen atom of  
16 the indole ring by an alkyl, haloalkyl, cyanoalkyl,  
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-  
18 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,  
19 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-  
20 morpholinyl)methyl, or tetrahydropyranylmethyl group,  
21 whether or not further substituted in the indole ring



- 1 to any extent and whether or not substituted in the  
2 tetramethylcyclopropyl ring to any extent[-];
- 3 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,  
4 its optical, positional, and geometric isomers, salts,  
5 and salts of isomers (Other names: APINACA, AKB48);
- 6 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its  
7 optical, positional, and geometric isomers, salts, and  
8 salts of isomers (Other names: PB-22; QUPIC);
- 9 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-  
10 carboxylate, its optical, positional, and geometric  
11 isomers, salts, and salts of isomers (Other names: 5-  
12 fluoro-PB-22; 5F-PB-22);
- 13 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-  
14 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,  
15 positional, and geometric isomers, salts, and salts of  
16 isomers (Other names: AB-FUBINACA); and
- 17 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-  
18 indazole-3-carboxamide, its optical, positional, and  
19 geometric isomers, salts, and salts of isomers (Other  
20 names: ADB-PINACA)."



1 SECTION 2. Section 329-18, Hawaii Revised Statutes, is  
2 amended by amending subsection (c) to read as follows:

3 "(c) Depressants. Unless listed in another schedule, any  
4 material, compound, mixture, or preparation containing any  
5 quantity of the following substances having a depressant effect  
6 on the central nervous system:

- 7 (1) Any compound, mixture, or preparation containing  
8 amobarbital, secobarbital, pentobarbital, or any salt  
9 thereof and one or more other active medicinal  
10 ingredients which are not listed in any schedule;
- 11 (2) Any suppository dosage form containing amobarbital,  
12 secobarbital, pentobarbital, or any salt of any of  
13 these drugs and approved by the Food and Drug  
14 Administration for marketing only as a suppository;
- 15 (3) Any substance that contains any quantity of a  
16 derivative of barbituric acid or any salt thereof,  
17 including the substance butalbital;
- 18 (4) Chlorhexadol;
- 19 (5) Embutramide (Tributame);
- 20 (6) Ketamine, its salts, isomers, and salts of isomers,  
21 also known as (+ or -)-2-(2-chlorophenyl)-2-  
22 (methylamino)-cyclohexanone;



- 1 (7) Lysergic acid;
- 2 (8) Lysergic acid amide;
- 3 (9) Methyprylon;
- 4 (10) Sulfondiethylmethane;
- 5 (11) Sulfonethylmethane;
- 6 (12) Sulfonmethane;
- 7 (13) Tiletamine/Zolazepam (Telazol, 2-(ethylamino)-2-(-
- 8 thienyl)-cyclohexanone, flupyrzapon) or any salts
- 9 thereof; [and]
- 10 (14) Gamma hydroxybutyric acid and its salts, isomers, and
- 11 salts of isomers that are contained in a drug product
- 12 for which an application has been approved under
- 13 section 505 of the federal Food, Drug, and Cosmetic
- 14 Act[-];
- 15 (15) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-
- 16 dihydropyridin-3-yl)benzotrile], including its
- 17 salts, isomers, and salts of isomers; and
- 18 (16) Alfaxalone 5[alpha]-pregnan-3[alpha]-ol-11,20-dione,
- 19 including its salts, isomers, and salts of isomers."

20 SECTION 3. Section 329-20, Hawaii Revised Statutes, is

21 amended by amending subsection (d) to read as follows:

1           "(d) Stimulants. Unless listed in another schedule, any  
2 material, compound, mixture, or preparation which contains any  
3 quantity of the following substances having a stimulant effect  
4 on the central nervous system, including its salts, isomers, and  
5 salts of such isomers whenever the existence of such salts,  
6 isomers, and salts of isomers is possible within the specific  
7 chemical designation:

- 8           (1) Cathine ((+)-norpseudoephedrine);
- 9           (2) Diethylpropion;
- 10          (3) Fencamfamin;
- 11          (4) Fenproporex;
- 12          (5) Mazindol;
- 13          (6) Mefenorex;
- 14          (7) Modafinil;
- 15          (8) Phentermine;
- 16          (9) Pemoline (including organometallic complexes and  
17             chelates thereof);
- 18          (10) Pipradrol;
- 19          (11) Sibutramine; [~~and~~]
- 20          (12) SPA (1-dimethylamino-1,2-diphenylethane,  
21             lefetamine) [-]; and
- 22          (13) Lorcaserin."



1           SECTION 4. Statutory material to be repealed is bracketed  
2 and stricken. New statutory material is underscored.  
3           SECTION 5. This Act shall take effect upon its approval.



**Report Title:**

Uniform Controlled Substances Act; Federal Conformity

**Description:**

Updates chapter 329, Hawaii Revised Statutes (HRS), to make it consistent with amendments to federal law on controlled substances, as required under section 329-11, HRS. (SB2882 HD2)

*The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.*

